Abstract The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low‐dose computed tomography screening, the frequent detection of ground‐glass opacities, and a rising incidence among never‐smokers, the diagnostic center of gravity has shifte...
Chao-Qi Zhang, Xuan-Yu Gu, Pan-Hong Wang et al.· Ca· 1 citation
Despite advances in targeted therapy and immune checkpoint inhibitors (ICIs), durable disease control remains elusive for most patients with non-small cell lung cancer (NSCLC), particularly those with advanced-stage disease. Therapeutic cancer vaccines offer the potential for sustained immune surveillance by inducing t...
Wei-Jing Liu, Jie-Fei Han, K. Fei et al.· Chinese Medical Journal - Pu...· 4 citations
In this issue of Cancer Cell, Li et al. report a first-in-human phase 1 study of SYS6010, an epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate, in advanced solid tumors. The study highlights how EGFR-directed therapy moves beyond kinase inhibition toward antigen-guided cytotoxic delivery in non-...
Li-Hui Liu, Kai-Lun Fei, Jie Wang· Cancer Cell· 0 citations
BACKGROUND
Transformed small-cell lung cancer (T-SCLC) is an increasingly recognized resistance mechanism in EGFR-mutant lung adenocarcinoma. This study aimed to identify early predictors of histologic transformation and evaluate post-transformation treatment outcomes.
METHODS
We retrospectively collected 163 T-SCLC...
